

Polsinelli Represents Sanacor, Inc. in Seed Financing

KANSAS CITY (February 18, 2025) Polsinelli congratulates its client Sanacor, Inc. (<https://www.sanacor.com/>), on its Seed Financing. Sanacor, Inc. is a biotechnology company focused on mitochondrial dysfunction in diabetic cardiovascular diseases (more than 500 million people are expected to develop diabetic cardiovascular disease by 2045, with associated healthcare costs projected at \$350 billion annually).

The financing was led by Venture Investors Health Fund (VI). The financing will help Sanacor move its lead compound forward towards human clinical studies and expand its biological foundation which is committed to finding disease modifying treatments for patients in need.

More information about the financing can be obtained here: [announcement](#).

The Polsinelli Venture Capital and Emerging Growth Companies team involved in the transaction included Chris Simpson, Laura Venn, and Izzy Drake.

About Polsinelli

Polsinelli is an Am Law 100 firm with more than 1,000 attorneys in over 20 offices nationwide. Recognized as one of the top firms for excellent client service and client relationships, Polsinelli is committed to meeting our clients' expectations of what a law firm should be. Our attorneys provide value through practical legal counsel infused with business insight, offering comprehensive corporate, transactional, litigation and regulatory services with a focus on health care, real estate, finance, technology, private equity and life sciences. Polsinelli PC, Polsinelli LLP in California, Polsinelli PC (Inc) in Florida.